Day One Biopharmaceuticals Inc (DAWN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Day One Biopharmaceuticals Inc stock (DAWN) is currently trading at $21.38. Day One Biopharmaceuticals Inc PS ratio (Price-to-Sales) is 14.00. Analyst consensus price target for DAWN is $21.50. WallStSmart rates DAWN as Sell.
- DAWN PE ratio analysis and historical PE chart
- DAWN PS ratio (Price-to-Sales) history and trend
- DAWN intrinsic value — DCF, Graham Number, EPV models
- DAWN stock price prediction 2025 2026 2027 2028 2029 2030
- DAWN fair value vs current price
- DAWN insider transactions and insider buying
- Is DAWN undervalued or overvalued?
- Day One Biopharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- DAWN Piotroski F-Score and Altman Z-Score
- DAWN analyst price target and Smart Rating
Day One Biopharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Day One Biopharmaceuticals Inc (DAWN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Day One Biopharmaceuticals Inc (DAWN) Key Strengths (3)
Revenue surging 83.90% year-over-year
84.93% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Day One Biopharmaceuticals Inc (DAWN) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 14.0x annual revenue
Very expensive at 5.0x book value
Supporting Valuation Data
Day One Biopharmaceuticals Inc (DAWN) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 83.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (14.00), Price/Book (5.02) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -22.70%, Operating Margin at -51.10%, Profit Margin at -67.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -22.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 83.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DAWN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DAWN's Price-to-Sales ratio of 14.00x trades 69% above its historical average of 8.29x (95th percentile), historically expensive. The current valuation is 0% below its historical high of 14x set in Mar 2026, and 181% above its historical low of 4.99x in May 2025. Over the past 12 months, the PS ratio has expanded from ~6.3x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Day One Biopharmaceuticals Inc (DAWN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Day One Biopharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 158M with 84% growth year-over-year. The company is currently unprofitable, posting a -67.8% profit margin.
Key Findings
Revenue growing at 84% YoY, reaching 158M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 26% of revenue (41M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -67.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -18M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Day One Biopharmaceuticals Inc maintain 84%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Day One Biopharmaceuticals Inc.
Bottom Line
Day One Biopharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 84% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -67.8% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Day One Biopharmaceuticals Inc(DAWN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and markets targeted therapies for patients with genetically defined cancers. The company is headquartered in South San Francisco, California.